Top

Published in:

01-09-2015 | Review

Amyloidosis in alkaptonuria

Authors: Lia Millucci, Daniela Braconi, Giulia Bernardini, Pietro Lupetti, Josef Rovensky, Lakshminaryan Ranganath, Annalisa Santucci

Published in: Journal of Inherited Metabolic Disease | Issue 5/2015

Abstract

Alkaptonuria (AKU) is an ultra-rare inborn error of metabolism developed from the lack of homogentisic acid oxidase activity, causing homogentisic acid (HGA) accumulation that produces an HGA-melanin ochronotic pigment, of hitherto unknown composition. Besides the accumulation of HGA, the potential role and presence of unidentified proteins has been hypothesized as additional causal factors involved in ochronotic pigment deposition. Evidence has been provided on the presence of serum amyloid A (SAA) in several AKU tissues, which allowed classifying AKU as a novel secondary amyloidosis. In this paper, we will briefly review all direct and indirect lines of evidence related to the presence of amyloidosis in AKU. We also report the first data on abnormal SAA serum levels in a cohort of AKU patients.

Abbott A (2011) Rare-disease project has global ambitions. Nature 472:17CrossRefPubMed

Aquaron R, Fayet G, Barthet C, Désiré S, Viallet F (1995) Parkinson disease and alkaptonuria: fortuitous association or striatonigral ochronosis? Rev Neurol (Paris) 151(1):63–66

Bely M, Apathy A (2012) Amyloid A deposition in rheumatoid arthritis: a retrospective clinicopathologic study of 161 autopsy patients. Amyloid 19:212–213CrossRefPubMed

Bernardini G, Laschi M, Geminiani M, Braconi D, Vannuccini E, Lupetti P, Manetti F, Millucci L, Santucci A (2015) Homogentisate 1,2 dioxygenase is expressed in brain: implications in alkaptonuria. J Inherit Metab Dis – in press

Braconi D, Laschi M, Taylor AM et al (2010a) Proteomic and redox-proteomic evaluation of homogentisic acid and ascorbic acid effects on human articular chondrocytes. J Cell Biochem 111:922–932CrossRefPubMed

Braconi D, Laschi M, Amato L et al (2010b) Evaluation of anti-oxidant treatments in an in vitro model of alkaptonuric ochronosis. Rheumatology (Oxford) 49:1975–1983CrossRef

Braconi D, Bianchini C, Bernardini G et al (2011) Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis. J Inherit Metab Dis 34:1163–1176CrossRefPubMed

Braconi D, Bernardini G, Bianchini C et al (2012) Biochemical and proteomic characterization of alkaptonuric chondrocytes. J Cell Physiol 227:3333–3343CrossRefPubMedCentralPubMed

Braconi D, Millucci L, Ghezzi L, Santucci A (2013) Redox proteomics gives insights into the role of oxidative stress in alkaptonuria. Expert Rev Proteomics 10:521–535CrossRefPubMed

Braconi D, Millucci L, Bernardini G, Santucci A (2015) Oxidative stress and mechanisms of ochronosis in alkaptonuria. Free Radic Biol Med - in press

Butterfield DA, Lauderback CM (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 32:1050–1060CrossRefPubMed

Castillo ECG, Kourí JB (2004) A new role for chondrocytes as non-professional phagocytes. An in vitro study. Microsc Res Tech 64:269–278CrossRefPubMed

Curtis SL, Roberts NB, Ranganath LR (2014) Interferences of homogentisic acid (HGA) on routine clinical chemistry assays in serum and urine and the implications for biochemical monitoring of patients with alkaptonuria. Clin Biochem 47:640–647CrossRefPubMed

Delevoye C, Giordano F, van Niel G, Raposo G (2011) Biogenesis of melanosomes - the chessboard of pigmentation. Med Sci (Paris) 27(2):153–162CrossRef

Dweck MR, Chow MW, Joshi NV et al (2012) Coronary arterial 18 F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol 59:1539–1548CrossRefPubMed

Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, Kelly JW (2006) Functional amyloid formation within mammalian tissue. PLoS Biol 4(1):e6CrossRefPubMedCentralPubMed

Giustarini D, Dalle-Donne I, Lorenzini S et al (2012) Protein thiolation index (PTI) as a biomarker of oxidative stress. Free Radical Biol Med 53:907–915CrossRef

Hegedus ZL (2000) The probable involvement of soluble and deposited melanins, their intermediates and the reactive oxygen side-products in human diseases and aging. Toxicology 145:85–101CrossRefPubMed

Helliwell TR, Gallagher JA, Ranganath L (2008) Alkaptonuria–a review of surgical and autopsy pathology. Histopathology 53:503–512PubMed

Hu KN, McGlinchey RP, Wickner RB, Tycko R (2011) Segmental polymorphism in a functional amyloid. Biophys J 101(9):2242–2250CrossRefPubMedCentralPubMed

Jiang Z, Lee JC (2014) Lysophospholipid-containing membranes modulate the fibril formation of the repeat domain of a human functional amyloid, pmel17. J Mol Biol 426(24):4074–4086CrossRefPubMed

Kamalvand G, Ali-Khan Z (2004) Immunolocalization of lipid peroxidation/advanced glycation end products in amyloid A amyloidosis. Free Radic Biol Med 36:657–664CrossRefPubMed

Lachmann HJ, Goodman HJ, Gilbertson JA et al (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361–2371CrossRefPubMed

Laschi M, Tinti L, Braconi D et al (2012) Homogentisate 1,2 dioxygenase is expressed in human osteoarticular cells: implications in alkaptonuria. J Cell Physiol 227:3254–3257CrossRefPubMedCentralPubMed

Leonhardt RM, Vigneron N, Hee JS, Graham M, Cresswell P (2013) Critical residues in the PMEL/Pmel17 N-terminus direct the hierarchical assembly of melanosomal fibrils. Mol Biol Cell 24(7):964–981CrossRefPubMedCentralPubMed

Magy N, Benson MD, Liepnieks JJ, Kluve-Beckerman B (2007) Cellular events associated with the initial phase of AA amyloidogenesis: insights from a human monocyte model. Amyloid 14:51–63CrossRefPubMed

Martin JP Jr, Batkoff B (1987) Homogentisic acid autoxidation and oxygen radical generation: implications for the etiology of alkaptonuric arthritis. Free Radic Biol Med 3:241–250CrossRefPubMed

McGlinchey RP, Yap TL, Lee JC (2011) The yin and yang of amyloid: insights from α-synuclein and repeat domain of Pmel17. Phys Chem Chem Phys 13(45):20066–20075CrossRefPubMedCentralPubMed

Millucci L, Spreafico A, Tinti L et al (2012) Alkaptonuria is a novel human secondary amyloidogenic disease. Biochim Biophys Acta 1822:1682–1691CrossRefPubMedCentralPubMed

Millucci L, Ghezzi L, Braconi D et al (2014a) Secondary amyloidosis in an alkaptonuric aortic valve. Int J Cardiol 172:e121–e123CrossRefPubMedCentralPubMed

Millucci L, Giorgetti G, Viti C et al (2014b) Chondroptosis in alkaptonuric cartilage. J Cell Physiol 230(5):1148-57

Millucci L, Ghezzi L, Paccagnini E et al (2014c) Amyloidosis, inflammation, and oxidative stress in the heart of an alkaptonuric patient. Mediat Inflamm 2014:258471

Millucci L, Ghezzi L, Bernardini G et al (2014d) Diagnosis of secondary amyloidosis in alkaptonuria. Diagn Pathol 9:185CrossRefPubMedCentralPubMed

Momohara S, Okamoto H, Yamanaka H (2008) Chondrocyte of rheumatoid arthritis serve as a source of intra-articular acute-phase serum amyloid A protein. Clin Chim Acta 398:155–156CrossRefPubMed

Nakamura T (2011) Amyloid A amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatments. Clin Exp Rheumatol 29:850–857PubMed

Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G (2009) Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 61:1435–1440CrossRefPubMed

Ranganath LR, Milan A, Hughes AT, et al (2014) Suitability of nitisinone in alkaptonuria 1 (SONIA 1): an international, multicenter, randomized, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-hour urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. Annals of the Rheumatic Diseases. doi:10.1136/annrheumdis-2014-206033

Rochin L, Hurbain I, Serneels L, Fort C, Watt B, Leblanc P, Marks MS, De Strooper B, Raposo G, van Niel G (2013) BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. Proc Natl Acad Sci U S A 25:110(26)

Selvi E, Manganelli S, Mannoni A, Benucci M, Minacci C, Marcolongo R (2000) Chronic ochronotic arthritis: clinical, arthroscopic, and pathologic findings. J Rheumatol 27:2272–2274PubMed

Selvi E, Garcia-Gonzalez E, Maggio R, Lorenzini S, Santucci A, Galeazzi M (2010) False proteinuria in patients with alkaptonuria. Clin Exp Rheumatol 28:591PubMed

Spencer JM, Gibbons CL, Sharp RJ, Carr AJ, Athanasou NA (2004) Arthroplasty for ochronotic arthritis: no failure of 11 replacements in 3 patients followed 6-12 years. Acta Orthop Scand 75:355–358CrossRefPubMed

Spreafico A, Millucci L, Ghezzi L et al (2013) Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria. Rheumatology (Oxford) 52:1667–1673CrossRef

Taylor AM, Wlodarski B, Prior IA et al (2010) Ultrastructural examination of tissue in a patient with alkaptonuric arthropathy reveals a distinct pattern of binding of ochronotic pigment. Rheumatology (Oxford) 49:1412–1414CrossRef

Theos AC, Watt B, Harper DC, Janczura KJ, Theos SC, Herman KE, Marks MS (2013) The PKD domain distinguishes the trafficking and amyloidogenic properties of the pigment cell protein PMEL and its homologue GPNMB. Pigment Cell Melanoma Res 26(4):470–486CrossRefPubMedCentralPubMed

Tinti L, Spreafico A, Braconi D et al (2010) Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model. J Cell Physiol 225:84–91CrossRefPubMed

Tinti L, Spreafico A, Chellini F, Galeazzi M, Santucci A (2011a) A novel ex vivo organotypic culture model of alkaptonuria-ochronosis. Clin Exp Rheumatol 29:693–696PubMed

Tinti L, Taylor AM, Santucci A et al (2011b) Development of an in vitro model to investigate joint ochronosis in alkaptonuria. Rheumatology (Oxford) 50:271–277CrossRef

Watt B, van Niel G, Raposo G (2013) Marks MS (2013) PMEL: a pigment cell-specific model for functional amyloid formation. Pigment Cell Melanoma Res 26(3):300–315CrossRefPubMedCentralPubMed

Westermark GT, Westermark P (2009) Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis. FEBS Lett 583:2685–2690CrossRefPubMed

Zatkova A (2011) An update on molecular genetics of Alkaptonuria (AKU). J Inherit Metab Dis 34:1127–1136CrossRefPubMed

Title: Amyloidosis in alkaptonuria
Authors: Lia Millucci
Daniela Braconi
Giulia Bernardini
Pietro Lupetti
Josef Rovensky
Lakshminaryan Ranganath
Annalisa Santucci
Publication date: 01-09-2015
Publisher: Springer Netherlands
Published in: Journal of Inherited Metabolic Disease / Issue 5/2015
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-015-9842-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Amyloidosis in alkaptonuria

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2015

Methylmalonic acidemia (MMA) in pregnancy: a case series and literature review

Propofol administration in patients with methylmalonic acidemia and intracellular cobalamin metabolism disorders: a review of theoretical concerns and clinical experiences in 28 patients

Loss of function mutation in glutamic pyruvate transaminase 2 (GPT2) causes developmental encephalopathy

Clinical onset and course, response to treatment and outcome in 24 patients with the cblE or cblG remethylation defect complemented by genetic and in vitro enzyme study data

Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetate

Homogentisate 1,2 dioxygenase is expressed in brain: implications in alkaptonuria

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page